Biopharmaceutical investment only reaching 1/10 of other competing countries

After the Korea Exchange created the ‘Exceptional Listing Clause through Technology Evaluation’ on December 2005, the total 27 biotechnology companies have acquired approval to go public through it until the end of 2015, and all of them were listed.

Biopharmaceutical companies which did not meet existing standards to go public – such as fulfillment of ordinary incomes – were given opportunitie...